HIV international clinical research: exploitation and risk.
This paper aims to show that to reduce the level of exploitation present in (some) international clinical trials, research sponsors must aim to provide both an ex-ante expected gain in utility and a fair ex-post distribution of benefits for research subjects. I suggest the following principles of fair risk distribution in international research as the basis of a normative definition of fairness: (a) Persons should not be forced (by circumstance) to gamble in order to achieve or protect basic goods; (b) In cases where one party is gambling with basic goods and the other party is not, the distribution of benefits and burdens must be arranged so that they are of greatest benefit to the worst off; (c) In relationships where one party is gambling for basic goods and the other party is not, the party gambling for basic goods must be assured of some guaranteed benefits in addition to the chance of getting some practical benefits. These principles are applied to the case of HIV international research. I conclude that the research (as described) is mutually advantageous but still exploitative because the distribution of surplus benefits is unfair. It is unfair because research subjects are gambling with and for basic goods but they are not assured of a fair ex-post distribution of benefits. Principles (b) and (c) are not satisfied. Research participants are not accorded enough guaranteed benefits to outweigh the risks they undertake.
Ballantyne
Angela
A
Centre for Human Bioethics, Monash University, Clayton, Victoria, Australia 3800. Ajbal14@student.monash.edu.au
D044966:Anti-Retroviral Agents / Q000600:supply & distribution / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics*; D019049:Developed Countries; D003906:Developing Countries; D004345:Drug Industry / Q000191:economics; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility; D006805:Human Experimentation / Q000941:ethics*; D006801:Humans; D010919:Placebos; D035842:Research Subjects; D018570:Risk Assessment / Q000941:ethics*; D012935:Social Justice; D035862:Vulnerable Populations
D044966:Anti-Retroviral Agents; D010919:Placebos